CC BY-NC-ND 4.0 · South Asian J Cancer 2014; 03(04): 192
DOI: 10.4103/2278-330X.142940
Editorial

Chronic myeloid leukemia in children, do we have all the answers?

Shweta Bansal
Department of Oncology, Division of Pediatric Oncology, Sir. Harkishandas Nurrottamdas Reliance Foundation Hospital, Mumbai, Maharashtra
› Author Affiliations
Source of Support: Nil.


Publication History

Article published online:
31 December 2020

© 2014. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Millot F, Traore P, Guilhot J, Nelken B, Leblanc T, Leverger G, et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics 2005;116:140-3.
  • 2 Linga VG, Ganta RR, Kalpathi KI, Gundeti S, Rajappa SJ, Digumarti R, et al. Response to imatainib mesylate in childhood myeloid leukemia in chronic phase. South Asian J Cancer 2014 ;3:203-5.
  • 3 Bansal S, Prabhash K, Parikh P. Chronic myeloid leukemia data from India. Indian J Med Paediatr Oncol 2013;34:154-8.
  • 4 Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Betrand Y, et al. Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukaemia (CML) in early chronic phase (CP): Results of the French national phase IV trial. Blood 2009;110:863. [Abstract].
  • 5 Suttorp M, Thiede C, Tauer JT, Roettgers S, Sedlacek P, Harbott J. Chronic myeloid leukemia in pediatrics - First results from study CML-PAED II. Blood 2009;114:145. [Abstract].